PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.07%
Revenue growth under 50% of MRVL's 7.20%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.43%
Gross profit growth 1.25-1.5x MRVL's 6.77%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
33.29%
EBIT growth above 1.5x MRVL's 14.12%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
33.29%
Operating income growth above 1.5x MRVL's 14.12%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
34.23%
Net income growth above 1.5x MRVL's 15.63%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
39.13%
EPS growth above 1.5x MRVL's 20.00%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
30.43%
Diluted EPS growth above 1.5x MRVL's 8.81%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-4.97%
Share reduction while MRVL is at 3.38%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
1.70%
Diluted share reduction more than 1.5x MRVL's 3.92%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-9.67%
Negative OCF growth while MRVL is at 1.58%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-6.30%
Negative FCF growth while MRVL is at 10.23%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
470.73%
10Y revenue/share CAGR above 1.5x MRVL's 310.13%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
195.45%
5Y revenue/share CAGR at 50-75% of MRVL's 310.13%. Martin Whitman would worry about a lagging mid-term growth trajectory.
-10.51%
Negative 3Y CAGR while MRVL stands at 212.77%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
1728.60%
10Y OCF/share CAGR above 1.5x MRVL's 563.63%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
533.44%
5Y OCF/share CAGR is similar to MRVL's 563.63%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
64.10%
3Y OCF/share CAGR under 50% of MRVL's 494.36%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
609.96%
Net income/share CAGR at 50-75% of MRVL's 924.66%. Martin Whitman might question if the firm’s product or cost base lags behind.
164.79%
Below 50% of MRVL's 924.66%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-30.83%
Negative 3Y CAGR while MRVL is 273.99%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1013.55%
Below 50% of MRVL's 6240.53%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
469.21%
Below 50% of MRVL's 6240.53%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
26.58%
3Y equity/share CAGR above 1.5x MRVL's 11.03%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.85%
Firm’s AR is declining while MRVL shows 2.08%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.46%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
0.40%
Asset growth well under 50% of MRVL's 3.72%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
9.90%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
902.10%
Debt growth far above MRVL's 23.52%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
2.21%
R&D growth drastically higher vs. MRVL's 3.34%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-8.64%
We cut SG&A while MRVL invests at 2.71%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.